Get alerts:Total revenue for the quarter ended June 30 was $0.7 million, compared with $28.9 million a year earlier. Chief Executive Officer Mike Exton said Lexicon completed enrollment in SONATA-HCM, a Phase III study evaluating sotagliflozin in patients with hypertrophic cardiomyopathy, or HCM. Lexicon expects to report top-line results from the trial in the first quarter of 2027. Lexicon may access an additional $20 million subject to clinical, regulatory and financial milestones, while a further $25 million tranche would require Hercules’ consent and meet specified timing requirements. About Lexicon Pharmaceuticals (NASDAQ:LXRX)Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform.